Answers are grounded in this paper and cite their sources.
This manuscript outlines a novel single-dose mRNA LNP protocol designed to eradicate latent Epstein-Barr Virus from resting memory B cells as a targeted curative therapy for Multiple Sclerosis. Current research establishes Epstein-Barr Virus infection as a primary prerequisite and driver of the autoimmune demyelination characterizing Multiple Sclerosis. Rather than relying on broad immunosuppression or chronic disease-modifying therapies this protocol utilizes a dual-payload system consisting of CRISPR Cas12a for structural viral cleavage and dCas9 for deep epigenetic silencing of viral promoters. By neutralizing the episomal DNA responsible for viral latency and molecular mimicry this approach aims to halt Multiple Sclerosis progression while preserving the host B cells and humoral immune memory. This preprint is submitted to foster collaboration and accelerate peer review within the neuroimmunology and precision genetic engineering communities.
No takes yet. Share an insight, caveat, or question.
Paul Hallelujah (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: